The current standard of care includes the use of endocrine therapies such as tamoxifen the oldest and most prescribed selective estrogen receptor modulator, anti-estrogens, selective estrogen receptor degraders, and aromatase inhibitors which are widely used for the treatment of ER+ BC. Here, ESR1 is linked to breast cancer.